Background Respiratory syncytial virus (RSV) is a leading cause of infant hospitalisation due to lower respiratory tract infections. Until 2022, prevention was limited to the costly monoclonal ...
Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He ...
COVID-19 vaccinations were shown to reduce virus-related hospitalizations and severe disease-associated outcomes in immunocompetent adults. The findings from a recently published JAMA Network Open ...
One potential new treatment could be a game-changer when it comes to universal protection against a variety of illnesses, including COVID-19, influenza, and spring pollen.
Stanford researchers develop breakthrough nasal spray vaccine that could potentially protect against a variety of infections, ...
Vaccines have traditionally worked by teaching the immune system to recognize a specific virus or bacterium—in effect, ...
Stanford Medicine researchers have developed an experimental nasal spray vaccine that protected mice against SARS‑CoV‑2, ...
Respiratory infection risk increases during winter due to a combination of environmental factors, seasonal immune changes, viral transmission dynamics, and behavioral shifts that collectively favor ...
A new multinational study from the INTERCOVID Consortium, including Ann & Robert H. Lurie Children's Hospital of Chicago, has ...
Intranasal boosting after prior intramuscular COVID vaccination induced strong mucosal IgA responses in a small human cohort. These antibodies showed markedly enhanced neutralising activity against ...
From early failures to prefusion F protein breakthroughs, RSV vaccine development has accelerated, reshaping prevention strategies for infants and older adults.
You can’t blame this one on the stork. After a brief baby bump early in the COVID-19 pandemic, birth rates in the US and other wealthy countries dropped as the public health emergency eased. That ...